Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/30152
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorVERRIER, Richard L.
dc.contributor.authorBORTOLOTTO, Alexandre L.
dc.contributor.authorSILVA, Bruna A.
dc.contributor.authorMARUM, Alexandre A.
dc.contributor.authorSTOCCO, Fernando G.
dc.contributor.authorEVARISTO, Ederson
dc.contributor.authorANTONIO, Victor Z. de
dc.contributor.authorSILVA, Anderson C.
dc.contributor.authorBELARDINELLI, Luiz
dc.date.accessioned2019-01-17T13:39:08Z-
dc.date.available2019-01-17T13:39:08Z-
dc.date.issued2018
dc.identifier.citationHEART RHYTHM, v.15, n.12, p.1882-1888, 2018
dc.identifier.issn1547-5271
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/30152-
dc.description.abstractBACKGROUND Pulmonary delivery of antiarrhythmic agents has the potential to increase rapidly targeted drug concentrations in pulmonary veins and left atrium to terminate atrial fibrillation (AF). OBJECTIVE We evaluated the efficacy of flecainide administered via intratracheal instillation in terminating AF in a reliable preclinical model. METHODS In 11 closed-chest anesthetized Yorkshire pigs, AF was induced by intrapericardial administration of acetylcholine (1 mL of 102.5 mM solution) followed by burst pacing and allowed to continue for 2 minutes before intratracheal flecainide (0.4 or 0.75 mg/kg) administration. RESULTS Both the 0.4-and 0.75-mg/kg doses of intratracheal flecainide significantly reduced AF duration by 35% (P = .02) and 54% (P = .001), respectively, compared to no-drug baseline. There was a strong inverse correlation (r(2) = 0.87; P = .03) between the duration of AF and the change in atrial depolarization duration in response to intratracheal flecainide. Induction of AF resulted in a marked increase in ventricular rate and corresponding reduction in mean arterial pressure, which returned to baseline levels within 5 minutes after conversion. CONCLUSION Intratracheal flecainide instillation is effective in rapidly converting AF to normal sinus rhythm and restoring mean arterial pressure and heart rate to baseline values. The basis for this efficacy is likely rapid absorption of the drug through the lungs and delivery as a first-pass bolus to the left atrial and ventricular chambers and then to the coronary arterial circulation. The antiAF effect of flecainide is inversely correlated with the drug's prolongation of atrial depolarization, implicating slowing of intra-atrial conduction as an important mechanism underlying conversion of AF to normal sinus rhythm.eng
dc.description.sponsorshipInCarda Therapeutics, Inc.
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INCeng
dc.relation.ispartofHeart Rhythm
dc.rightsrestrictedAccesseng
dc.subjectAtrial fibrillationeng
dc.subjectAtrial depolarization durationeng
dc.subjectFlecainideeng
dc.subjectIntratracheal instillationeng
dc.subjectPulmonary deliveryeng
dc.subject.othersodium-channel blockeng
dc.subject.otherantiarrhythmic-drug therapyeng
dc.subject.otherranolazineeng
dc.subject.othermanagementeng
dc.subject.otherstrategyeng
dc.subject.otherpotenteng
dc.titleAccelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine modeleng
dc.typearticleeng
dc.rights.holderCopyright ELSEVIER SCIENCE INCeng
dc.identifier.doi10.1016/j.hrthm.2018.06.036
dc.identifier.pmid29958990
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalVERRIER, Richard L.:Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Med Sch, Boston, MA 02215 USA
hcfmusp.author.externalBELARDINELLI, Luiz:InCarda Therapeut Inc, Newark, CA USA
hcfmusp.description.beginpage1882
hcfmusp.description.endpage1888
hcfmusp.description.issue12
hcfmusp.description.volume15
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000451448600028
hcfmusp.origem.id2-s2.0-85051046946
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAlboni P, 2004, NEW ENGL J MED, V351, P2384, DOI 10.1056/NEJMoa041233eng
hcfmusp.relation.referenceAlboni P, 2010, HEART, V96, P546, DOI 10.1136/hrt.2009.187963eng
hcfmusp.relation.referenceAliot E, 2011, EUROPACE, V13, P161, DOI 10.1093/europace/euq382eng
hcfmusp.relation.referenceAndrade JG, 2018, HEART RHYTHM, V15, P9, DOI 10.1016/j.hrthm.2017.10.002eng
hcfmusp.relation.referenceBelardinelli L, 2017, CIRCULATION, V136eng
hcfmusp.relation.referenceBelardinelli L, 2017, CIRCULATION, V136eng
hcfmusp.relation.referenceBelardinelli L, 2013, J PHARMACOL EXP THER, V344, P23, DOI 10.1124/jpet.112.198887eng
hcfmusp.relation.referenceBoriani G, 2004, DRUGS, V64, P2741, DOI 10.2165/00003495-200464240-00003eng
hcfmusp.relation.referenceBurashnikov A, 2007, CIRCULATION, V116, P1449, DOI 10.1161/CIRCULATIONAHA.107.704890eng
hcfmusp.relation.referenceBurashnikov A, 2012, J PHARMACOL EXP THER, V340, P161, DOI 10.1124/jpet.111.186395eng
hcfmusp.relation.referenceBurashnikov A, 2009, EXPERT OPIN EMERG DR, V14, P233, DOI 10.1517/14728210902997939eng
hcfmusp.relation.referenceEverett TH, 2001, IEEE T BIO-MED ENG, V48, P969, DOI 10.1109/10.942586eng
hcfmusp.relation.referenceHuang SY, 2016, INT J CARDIOL, V202, P846, DOI 10.1016/j.ijcard.2015.10.004eng
hcfmusp.relation.referenceKirchhof P, 2016, EUR J CARDIO-THORAC, V50, pE1, DOI [10.1093/eurheartj/ehw210, 10.1093/ejcts/ezw313]eng
hcfmusp.relation.referenceKRISHNAN SC, 1993, CIRCULATION, V87, P562, DOI 10.1161/01.CIR.87.2.562eng
hcfmusp.relation.referenceKumar K, 2009, J CARDIOVASC ELECTR, V20, P796, DOI 10.1111/j.1540-8167.2009.01437.xeng
hcfmusp.relation.referenceMurdock DK, 2010, J ATR FIBRILLATION, V2, P705eng
hcfmusp.relation.referencePEREZVIZCAINO F, 1991, BRIT J PHARMACOL, V104, P726, DOI 10.1111/j.1476-5381.1991.tb12495.xeng
hcfmusp.relation.referencePiccini JP, 2016, LANCET, V388, P829, DOI 10.1016/S0140-6736(16)31277-6eng
hcfmusp.relation.referenceSardar MR, 2016, HEART FAIL CLIN, V12, P205, DOI 10.1016/j.hfc.2015.08.017eng
hcfmusp.relation.referenceSicouri S, 2013, HEART RHYTHM, V10, P1036, DOI 10.1016/j.hrthm.2013.03.023eng
hcfmusp.relation.referenceStocco FG, 2018, J CARDIOVASC PHARM, V72, P129, DOI 10.1097/FJC.0000000000000605eng
hcfmusp.relation.referenceTJANDRAMAGA TB, 1986, BRIT J CLIN PHARMACO, V22, P309, DOI 10.1111/j.1365-2125.1986.tb02892.xeng
hcfmusp.relation.referenceVerrier RL, 2016, HEART RHYTHM, V13, P953, DOI 10.1016/j.hrthm.2015.11.019eng
hcfmusp.relation.referenceZimetbaum P, 2012, CIRCULATION, V125, P381, DOI 10.1161/CIRCULATIONAHA.111.019927eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1556-3871
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2022-06-10-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC


Files in This Item:
File Description SizeFormat 
art_VERRIER_Accelerated_conversion_of_atrial_fibrillation_to_normal_sinus_2018.PDF.pdf
  Restricted Access
publishedVersion (English)892.04 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.